Myeloma 2016: Panel discussion on novel treatments
Keith Stewart et al.
The role of proteasome inhibitors in multiple myeloma
Daratumumab shows remarkable benefit in relapsed or refractory multiple myeloma in the POLLUX trial
PET-CT vs MRI in multiple myeloma
What’s new in minimal residual disease (MRD) detection in myeloma?